Dasatinib (Figure 8), a small molecule inhibitor of Src and abl proteins, has been approved for imatinib refractory chronic myelogenous leukemia and bcr–abl positive acute lymphoblastic leukemia treatment. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.